<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="92233">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01675154</url>
  </required_header>
  <id_info>
    <org_study_id>3940</org_study_id>
    <secondary_id>FD-R-003940</secondary_id>
    <nct_id>NCT01675154</nct_id>
  </id_info>
  <brief_title>Phase 2 Study of Orlistat and SLx-4090 for the Treatment of Type 1 Hyperlipoproteinemia</brief_title>
  <official_title>Phase 2 Study of Orlistat and SLx-4090 for Teh Treatment of Type 1 Hyperlipoproteinemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Texas Southwestern Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Texas Southwestern Medical Center</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <authority>United States: FDA:   Office of Orphan Products Development</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Funding Source - FDA OOPD

      This study is being done to find out whether an investigational (not approved by FDA ) drug
      called SLx-4090 or Orlistat (FDA approved medication for weight loss) when given  alone or
      in combination can treat the  high blood fat (elevated triglycerides)levels found in the
      condition Type 1 Hyperlipoproteinemia (T1HLP)  better or more safely than low fat diet
      alone, the current standard medical care.

      It is also not clear whether Orlistat, that is  FDA approved for weight loss, is effective
      in lowering blood fat levels in patients with Type 1 hyperlipoproteinemia (T1HLP).  The
      researchers are interested in learning whether any one of these drugs when given alone or in
      combination is more effective and safe in treating T1HLP.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>August 2013</start_date>
  <completion_date type="Anticipated">December 2016</completion_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Change in serum triglycerides from baseline for each crossover arm phase of placebo/placebo, orlistat/placebo, orlistat/SLx-4090, SLx-4090/placebo</measure>
    <time_frame>Every  every 4 weeks at the end of each phase for 3 draws</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Type 1 Hyperlipoproteinemia</condition>
  <arm_group>
    <arm_group_label>SLx-4090 placebo/Orlistat Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Slx-4090(placebo) is dosed as 2 tablets  of 100 mg,  three times per day with meals.
Orlistat (placebo) is dosed as 2 capsules of 60 mg, three times per day with meals.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Orlistat/placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Orlistat two capsules 60mg each, three times per day with meals. Placebo for SLx-4090, 2 tablets  100mg each, three times per day with meals.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Orlistat placebo /Slx-4090</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Orlistat placebo  2 capsules, 60mg each three times per day with meals. Slx-4090 2 tablets, 100mg each. three times per day with meals.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Orlistat/SLx-4090</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Orlistat, 2 capsules 60 mg each, three times per day with meals. SLx-4090 2 tablets 100mg each, three times per day with meals.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SLx-4090 placebo</intervention_name>
    <arm_group_label>SLx-4090 placebo/Orlistat Placebo</arm_group_label>
    <arm_group_label>Orlistat/placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Orlistat Placebo</intervention_name>
    <arm_group_label>SLx-4090 placebo/Orlistat Placebo</arm_group_label>
    <arm_group_label>Orlistat placebo /Slx-4090</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Orlistat</intervention_name>
    <arm_group_label>Orlistat/placebo</arm_group_label>
    <arm_group_label>Orlistat/SLx-4090</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Slx-4090</intervention_name>
    <arm_group_label>Orlistat placebo /Slx-4090</arm_group_label>
    <arm_group_label>Orlistat/SLx-4090</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Type I hyperlipoproteinemia.

          -  Fasting serum triglyceride levels of greater than 1000 mg/dL.

          -  Age &gt; 12 years

        Exclusion Criteria:

          -  Secondary hypertriglyceridemias due to diabetes, renal disease, hypothyroidism,
             alcoholism and drug therapy such as estrogens  and   estrogen analogues, steroids,
             HIV-protease inhibitors, retinoic acid  derivatives and interferons.

          -  Pregnant or lactating women

          -  Significant liver disease (elevated transaminases &gt; 2 times upper limit of normal)

          -  Alcohol abuse (&gt; 7 drinks or 84 g per week for women and &gt; 14 drinks for men or 168 g
             per week for men)

          -  Drug use (cocaine, marijuana, LSD, etc.)

          -  Major surgery in the past three months

          -  Congestive heart failure

          -  Serum creatinine greater than 2.5 mg/dL

          -  Cancer within the past five years

          -  Gastrointestinal surgery in the past

          -  Current therapy with anti-coagulants, digoxin and anti-arrhythmics

          -  Chronic malabsorption syndromes

          -  Cholestasis

          -  Acute illnesses such as acute pancreatitis in the last 8 weeks
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>13 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Abhimanyu Garg, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UT Southwestern Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Claudia Quittner, RN, BSN, MS</last_name>
    <phone>214-648-9296</phone>
    <email>claudia.quittner@utsouthwestern.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Zahid Ahmad, M.D.</last_name>
    <phone>214-648-2377</phone>
    <email>zahid.ahmad@utsouthwestern.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>UT Southwestern Medical Center 5323 Harry Hines Blvd</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390-8537</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Abhimanyu Garg, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Zahid Ahmad, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2013</verification_date>
  <lastchanged_date>July 22, 2013</lastchanged_date>
  <firstreceived_date>August 27, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Texas Southwestern Medical Center</investigator_affiliation>
    <investigator_full_name>Abhimanyu Garg</investigator_full_name>
    <investigator_title>PI</investigator_title>
  </responsible_party>
  <keyword>hypertriglyceridemia</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hyperlipoproteinemias</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Orlistat</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
